High-density lipoprotein subfractions and their oxidized subfraction particles in patients with chronic kidney disease

Journal of Atherosclerosis and Thrombosis

Volumn 23, Issue 1, 2016, Pages 81-94

  Honda, Hirokazu ^a   Hirano, Tsutomu ^b   Ueda, Masashi ^c   Kojima, Shiho ^c   Mashiba, Shinichi ^c   Hayase, Yasuyuki ^c   Michihata, Tetsuo ^d   Shibata, Takanori ^b  

^a SHOWA UNIVERSITY KOTO TOYOSU HOSPITAL   (Japan)

^b SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Ikagaku Co Ltd   (Japan)

^d Department of Dialysis   (Japan)

Author keywords

CVD events; HDL subfraction; Oxidized HDL

Indexed keywords

APOLIPOPROTEIN; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; APOLIPOPROTEIN A1; OXYGEN;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; BRAIN INFARCTION; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DISEASE SEVERITY; FEMALE; FRACTIONATION; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PROSPECTIVE STUDY; RISK FACTOR; UNSTABLE ANGINA PECTORIS; BLOOD; CHEMISTRY; CHRONIC KIDNEY FAILURE; INFLAMMATION; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODEL;

AGED; APOLIPOPROTEIN A-I; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INFLAMMATION; LIPOPROTEINS, HDL; MALE; MALONDIALDEHYDE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OXIDATIVE STRESS; OXYGEN; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS;

EID: 84953455470     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.30015     Document Type: Article

References (39)

1. Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J, Qizilbash N, Peto R, Collins R. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55, 000 vascular deaths. Lancet. 2007; 370: 1829-39
2. Boekholdt SM, Arsenault BJ, Mora S, Pedersen TR, LaRosa JC, Nestel PJ, Simes RJ, Durrington P, Hitman GA, Welch KM, DeMicco DA, Zwinderman AH, Clearfield MB, Downs JR, Tonkin AM, Colhoun HM, Gotto AM Jr, Ridker PM, Kastelein J. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA. 2012; 307: 1302-1309
3. Kovesdy CP, Anderson JE, Kalantar-Zadeh K: Inverse association between lipid levels and mortality in men with chronic kidney disease who are not yet on dialysis: Effects of case mix and the malnutrition-inflammation-cachexia syndrome. J Am Soc Nephrol 2007; 18: 304-11
4. Liu Y, Coresh J, Eustace JA, Longenecker JC, Jaar B, Fink NE, Tracy RP, Powe NR, Klag MJ: Association between cholesterol level and mortality in dialysis patients: Role of inflammation and malnutrition. JAMA 2004; 291: 451-59
5. Zewinger S, Speer T, Kleber ME, Scharnagl H, Scharnagl H, Woitas R, Lepper PM, Pfahler K, Seiler S, Heine GH, März W, Silbernagel G, Fliser D. HDL cholesterol is not associated with lower mortality in patients with kidney dysfunction. J Am Soc Nephrol. 2014; 25: 1073-82
6. Lamprea-Montealegre JA, Astor BC, McClelland RL, de Boer IH, Burke GL, Sibley CT, O’Leary D, Sharrett AR, Szklo M: CKD, plasma lipids, and common carotid intima-media thickness: Results from the multi-ethnic study of atherosclerosis. Clin J Am Soc Nephrol 7: 1777-1785, 2012
7. Kaysen GA. Lipid and lipoprotein metabolism in chronic kidney disease. J Ren Nutr. 2009; 19: 73-7
8. Keane WF, Tomassini JE, Neff DR. Lipid abnormalities in patients with chronic kidney disease: implications for the pathophysiology of atherosclerosis. J Atheroscler Thromb. 2013; 20: 123-33.
9. Navab M, Reddy ST, Van Lenten BJ, Anantharamaiah GM, Fogelman AM. The role of dysfunctional HDL in atherosclerosis. J Lipid Res. 2009; 50 Suppl: S145-9
10. Riwanto M, Landmesser U. High density lipoproteins and endothelial functions: mechanistic insights and alterations in cardiovascular disease. J Lipid Res. 2013; 54: 3227-43
11. Huang Y, Didonato JA, Levison BS, Schmitt D, Li L, Wu Y, Buffa J, Kim T, Gerstenecker GS, Gu X, Kadiyala CS, Wang Z, Culley MK, Hazen JE, Didonato AJ, Fu X, Berisha SZ, Peng D, Nguyen TT, Liang S, Chuang CC, Cho L, Plow EF, Fox PL, Gogonea V, Tang WH, Parks JS, Fisher EA, Smith JD, Hazen SL. An abundant dysfunctional apolipoprotein A1 in human atheroma. Nat Med. 2014; 20: 193-203
12. Yan Wang, Liang Ji, Rengui Jiang, Lemin Zheng, Dong-hui Liu. Oxidized High-Density Lipoprotein Induces the Proliferation and Migration of Vascular Smooth Muscle Cells by Promoting the Production of ROS. J Atheroscler Thromb. 2014; 21: 204-216
13. Yamamoto S, Yancey PG, Ikizler TA, Jerome WG, Kaseda R, Cox B, Bian A, Shintani A, Fogo AB, Linton MF, Fazio S, Kon V. Dysfunctional high-density lipoprotein in patients on chronic hemodialysis. J Am Coll Cardiol. 2012; 60: 2372-79
14. Kalantar-Zadeh K, Kopple JD, Kamranpour N, Fogelman AM, Navab M. HDL-inflammatory index correlates with poor outcome in hemodialysis patients. Kidney Int. 2007; 72: 1149-56
15. Honda H, Ueda M, Kojima S, Mashiba S, Michihata T, Takahashi K, Shishido K, Akizawa T. Oxidized high-density lipoprotein as a risk factor for cardiovascular events in prevalent hemodialysis patients. Atherosclerosis 2012; 220: 493-501
16. Honda H, Ueda M, Kojima S, Mashiba S, Suzuki H, Hosaka N, Hirai Y, Nakamura M, Nagai H, Kato N, Mukai M, Watanabe M, Takahashi K, Shishido K, Akizawa T. Oxidized high-density lipoprotein is associated with protein-energy wasting in maintenance hemodialysis patients. Clin J Am Soc Nephrol 2010; 5: 1021-28
17. Bulum T, Kolaric B, Duvnjak L. Lower levels of total HDL and HDL3 cholesterol are associated with albuminuria in normoalbuminuric Type 1 diabetic patients. J Endocrinol Invest. 2013; 36: 574-8
18. Samouilidou E, Karpouza A, Grapsa E, Tzanatou-Exarchou H. Serum oxidized LDL is inversely associated with HDL2-cholesterol subclass in renal failure patients on hemodialysis Nephron Clin Pract. 2010; 115: c289-94
19. Piperi C, Kalofoutis C, Tzivras M, Troupis T, Skenderis A, Kalofoutis A. Effects of hemodialysis on serum lipids and phospholipids of end-stage renal failure patients. Mol Cell Biochem. 2004; 265: 57-61
20. Homma K, Homma Y, Shiina Y, Shinohara K, Suzuki M, Fujishima S, Hayashi K, Hori S, Itoh H. Skew of plasma low- and high-density lipoprotein distributions to less dense subfractions in normotriglyceridemic chronic kidney disease patients on maintenance hemodialysis treatment. Nephron Clin Pract. 2013; 123: 41-45
21. Hirano T, Nohtomi K, Koba S, Muroi A, Ito Y. A simple and precise method for measuring HDL-cholesterol subfractions by a single precipitation followed by homogenous HDL-cholesterol assay. J Lipid Res. 2008; 49: 1130-6
22. Ueda M, Hayase Y, Mashiba S. Establishment and evaluation of 2 monoclonal antibodies against oxidized apolipoprotein A-I apoA-I. and its application to determine blood oxidized apoA-I levels. Clin Chim Acta 2007; 378: 105-11
23. Holzer M, Birner-Gruenberger R, Stojakovic T, El-Gamal D, Binder V, Wadsack C, Heinemann A, Marsche G. Uremia alters HDL composition and function. J Am Soc Nephrol. 2011; 22: 1631-41
24. Brunzell JD, Zambon A, Deeb SS. The effect of hepatic lipase on coronary artery disease in humans is influenced by the underlying lipoprotein phenotype. Biochim Biophys Acta. 2012; 1821: 365-372
25. Calabresi L, Simonelli S, Conca P, Busnach G, Cabibbe M, Gesualdo L, Gigante M, Penco S, Veglia F, Franceschini G. Acquired lecithin: cholesterol acyltransferase deficiency as a major factor in lowering plasma HDL levels in chronic kidney disease. J Intern Med. 2015; 277: 552-561
26. González AI, Schreier L, Elbert A. Berg G, Beresan H, López G, Wikinski R. Lipoprotein alterations in hemodialysis: differences between diabetic and nondiabetic patients. Metab Clin Exp. 2003; 52: 116-121
27. Vaziri ND. Causes of dysregulation of lipid metabolism in chronic renal failure. Semin Nephrol. 2009: 22; 644-651
28. Gugliucci A, Menini T. Paraoxonase 1 and HDL maturation. Clin Chim Acta. 2015; 439: 5-13
29. Mackness B, Durrington P, McElduff P, Yarnell J, Azam N, Watt M, Mackness M. Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation. 2003; 107: 2775-2779
30. Kratzer A, Giral H, Landmesser U. High-density lipoproteins as modulators of endothelial cell functions: alterations in patients with coronary artery disease. Cardiovasc Res 2014; 103: 350-361
31. Huang Y, Wu Z, Riwanto M, Gao S, Levison BS, Gu X, Fu X, Wagner MA, Besler C, Gerstenecker G, Zhang R, Li XM, DiDonato AJ, Gogonea V, Tang WH, Smith JD, Plow EF, Fox PL, Shih DM, Lusis AJ, Fisher EA, DiDonato JA, Landmesser U, Hazen SL. Myeloperoxidase, paraoxonase-1, and HDL form a functional ternary complex. J Clin Invest 2013; 123: 3815-3828
32. Kennedy DJ, Tang WH, Fan Y, Wu Y, Mann S, Pepoy M, Hazen SL. Diminished antioxidant activity of high-density lipoprotein-associated proteins in chronic kidney disease. J Am Heart Assoc. 2013; 2: e000104
33. Gugliucci A, Kotani K, Kimura S. Paraoxonase 1 in chronic kidney failure. J Lipids. 2012; 2012: 726048
34. Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, French BC, Phillips JA, Mucksavage ML, Wilensky RL, Mohler ER, Rothblat GH, Rader DJ. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. New Engl J Med 2011; 364: 127-35
35. Linsel-Nitschke P, Jansen H, Aherrarhou Z, Belz S, Mayer B, Lieb W, Huber F, Kremer W, Kalbitzer HR, Erdmann J, Schunkert H. Macrophage cholesterol efflux correlates with lipoprotein subclass distribution and risk of obstructive coronary artery disease in patients undergoing coronary angiography. Lipid Health Dis 2009; 8: 14
36. Williams RT, Feldman DE. Prospective study of coronary heart disease vs. HDL2, HDL3, and other lipoproteins in Gofman’s Livermore Cohort. Atherosclerosis 2011; 214: 196-202
37. Johansson J, Carlson LA, Landou C, Hamsten A. High density lipoproteins and coronary atherosclerosis. A strong inverse relation with the largest particles is confined to normotriglyceridemic patients. Arterioscler Thromb 1991; 11: 174-82
38. Noori N, Caulfield MP, Salameh WA, Reitz RE, Nicholas SB, Molnar MZ, Nissenson AR, Kovesdy CP, Kalantar- Zadeh K. Novel lipoprotein subfraction and size measurements in prediction of mortality in maintenance hemodialysis patients. Clin J Am Soc Nephrol. 2011; 6: 2861-70
39. Shoji T, Fukumoto M, Kimoto E, Shinohara K, Emoto M, Tahara H, Koyama H, Ishimura E, Nakatani T, Miki T, Tsujimoto Y, Tabata T, Nishizawa Y. Antibody to oxidized low-density lipoprotein and cardiovascular mortality in end-stage renal disease. Kidney Int. 2002; 62: 2230-7